Jasper Therapeutics, Inc. (JSPR) Form 8-K — Jun 9, 2026
Jasper Therapeutics received a notice from Nasdaq on June 3, 2026, indicating that its voting common stock has failed to maintain the minimum $1.00 bid price for 30 consecutive business days. The company has been granted an initial 180 calendar day period, or until November 30, 2026, to regain compliance by maintaining a bid price of at least $1.00 for ten consecutive business days. If Jasper Therapeutics is unable to regain compliance by the deadline, it may be eligible for a second 180-day cure period provided it meets other listing standards and notifies Nasdaq of its intent to cure, potentially via a reverse stock split.
Key figures
- Minimum bid price
- $1.00
- Days non compliant
- 30 consecutive business days
- Cure period end date
- November 30, 2026
- Warrant exercise price
- $115.00
- Compliance cure duration
- 10 consecutive business days
Price after filing
Close on the filing date to close N calendar days later (from $0.47). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.